Revival of Plasmin as a Therapeutic Agent?

D. Collen

doi:10.1055/s-0037-1616125

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2001; 86(03): 731-732
DOI: 10.1055/s-0037-1616125

Commentary

Schattauer GmbH

Revival of Plasmin as a Therapeutic Agent?

Autor*innen

D. Collen

¹Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium and Center for Transgene

Abstract

Volltext

Referenzen

References
1 Marder VJ, Landskroner K, Novokhatny V, Zimmerman TP, Kong M, Kanouse JJ, Jesmok G. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001; 86: 739-45.
2 Nagai N, De Mol M, Van Hoef B, Verstreken M, Collen D. Depletion of circulating α₂-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization. Blood 2001; 97: 3086-92.
3 US 3,950,513. Process of stabilizing therapeutically useful plasmin solutions. Jensen VJ (inventor); Novo Terapeutisk Laboratorium (assignee); April 13, 1976.
4 Clifton EE. The use of plasmin in humans. Ann New York Acad Sci. 1957; 68: 209-29.
5 Collen D, Wiman B. Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. Blood 1979; 53: 313-24.
6 Whitefleet-Smith J, Rosen E, McLinden J, Poplis VA, Fraser MJ, Tomlinson JE, McLean JW, Castellino FJ. Expression of human plasminogen cDNA in a baculovirus vector-infected insect cell system. Arch Biochem Biophys 1989; 271: 390-9.
7 Sottrup-Jensen L, Petersen TE, Magnusson S. In: Atlas of Protein Sequence and Structure, Dayhoff M ed. National Biomedical Research Foundation, Washington; 1987; Vol (05) (Suppl. 03) 91.
8 Shi GY, Wu HL. Isolation and characterization of microplasminogen. J Biol Chem 1988; 263: 17071-5.
9 US patent 5,288,489. Fibrinolysis and fibrinogenolysis treatment. Reich E., Easton T.G. (inventors); Orion Therapeutic Systems (assignee); February 22, 1994.
10 UK 0031196.9. Recombinant human plasminogen and plasmin: Methods for high yield production, stabilization and use for treatment. Collen D. (inventor); Thromb-X, NV (assignee); December 21, 2000.